Valeant's meltdown claims another top exec, this time at shareholder Sequoia

Sequoia Fund chief Robert Goldfarb bowed out of his post Wednesday after his big bet on Valeant Pharmaceuticals ($VRX) turned up sour. One of the embattled drugmaker's biggest shareholders, Sequoia at one point had 30% of its capital tied up in Valeant, MarketWatch reports. Report

Read more on